Journal
503A vs 503B: The Two Kinds of Compounding Pharmacy, and Why the Letter Matters in 2026
Released: Last reviewed:
The short answer
Federal law splits compounding into two lanes. 503A pharmacies compound patient-specific prescriptions — one order, one patient — under primarily state board of pharmacy oversight, following USP standards (the 795/797 framework). 503B outsourcing facilities registered with the FDA may produce larger batches — including office stock without patient-specific prescriptions — under federal CGMP (current good manufacturing practice), with FDA inspection authority. Why the letter decides so much in 2026: with the semaglutide and tirzepatide shortages resolved (December 2024 and February 2025), the 503B bulk-substance lane for these molecules closed — effectively March 19, 2025 — while the 503A patient-specific lane remains open where a prescriber documents an individual clinical need (the 21 USC 353a pathway our legality guide maps), with the FDA's April 30, 2026 proposal not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list still awaiting a final decision as of October 15, 2026. Translation: essentially every legitimate compounded GLP-1 sold today ships from a 503A on a documented-need prescription — which is exactly what to verify.
What each label tells you, and what to check
Neither letter is a quality verdict by itself — excellent and mediocre operations exist in both — but each sets the oversight you're relying on and the questions to ask. For a 503A (the lane you'll almost certainly be in): the checks are state-shaped — active licensure in the pharmacy's home state and a non-resident license in yours (the two-lookup drill every state guide teaches), disciplinary history on those boards, accreditation signals, and the COA request that substitutes batch data for federal CGMP's absence. For a 503B claim on a GLP-1 in 2026: the claim itself now warrants scrutiny — ask under exactly what basis the product is produced post-shortage, because the bulk lane's closure is the whole regulatory story of this market, and NexLife's plan pages illustrate the norm: they name Absolute Pharmacy (Lutz, Florida), Premium Compounding (Decatur, Alabama) and Boudreaux's New Drug Store (Lake Charles, Louisiana), all state-licensed 503A pharmacies. The 503A lane is policed too: on September 18, 2026 the FDA warned Empower Pharmacy that its compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products." The rule of thumb that survives every detail: the letter tells you which rulebook applies; the lookups, records, and COA tell you whether this operation follows it — and a program that can't say which letter its pharmacy is has failed a simpler test than either.
Questions people ask
What's the difference between a 503A and 503B pharmacy?
503A: patient-specific prescriptions, one order per patient, primarily state-board oversight under USP standards. 503B: FDA-registered outsourcing facilities producing larger batches (including office stock) under federal CGMP with FDA inspection. Different rulebooks — neither letter alone is a quality guarantee.
Can 503B facilities still make compounded GLP-1s in 2026?
The 503B bulk-substance lane for semaglutide and tirzepatide closed after the shortages resolved (effectively March 19, 2025), and the FDA proposed on April 30, 2026 not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list (no final decision as of October 15, 2026). Today's legitimate compounded GLP-1s ship from 503A pharmacies on patient-specific, documented-need prescriptions.
Which is safer for compounded tirzepatide — 503A or 503B?
In 2026 the practical question is different: you'll be in the 503A lane, so safety comes from verification — the pharmacy's home-state license, the non-resident license in your state, disciplinary history, and a lot-matched COA. A 503B claim on a GLP-1 today warrants asking what legal basis supports it.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.